Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Rivo Health vs Shapely

Rivo Health
Graded #89

Higher grade

vs+6.299999999999997
Shapely
Graded #225

Lower grade

The verdict

Rivo Health takes it — 71.7/100 to 65.4/100.

Rivo Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Rivo Health is a large nationwide GLP-1 telehealth program (115,000+ members, Trustpilot 4.7) offering compounded semaglutide and tirzepatide as both injections and oral options, starting around $149/mo for…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueRivo Health +29
74
45
Dose & formulationRivo Health +22
75
53
Clinical oversightShapely +17
77
94
Labs & monitoringShapely +10
63
73
FulfillmentRivo Health +6
84
78
Contract termsShapely +14
41
55
Rivo Health · left barShapely · right bar

The numbers

MetricRivo HealthShapely
WeighScore71.7/10065.4/100
GradeCC
Scorecard rank#89#225
Semaglutide$149/mo (compounded)Not disclosed
Tirzepatide$199/mo (compounded)Not disclosed
CoverageAll 50 states4 states
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
Rivo Health

Graded #89 · C

Strengths

  • Compounded semaglutide and tirzepatide as both injections and oral options, starting around $149/mo (sema) and $199/mo (tirz)
  • Bundles dietitians, live workouts, support groups and mental-health coaching with the medication, not just a prescription
  • Insurance concierge to maximize coverage, FSA/HSA eligible, with multi-month plans that cut the price further
  • Large, established program (115,000+ members, Trustpilot 4.7) available nationwide

Where it loses points

  • Uses partner compounding pharmacies it doesn't name on the site
  • Headline prices are Spring-sale rates — everyday cost is higher and the deepest discounts need a 6-month commitment
  • Weight loss is one of several verticals (ED, longevity, sleep, hair, skin), not a single focus
  • Some bundled perks (e.g. meal prep) are paid add-ons rather than included
Shapely

Graded #225 · C

Strengths

  • Founded by Dr. Justin Zaghi, MD/MBA — Harvard-trained, board-certified in internal medicine and obesity medicine, with Medical Director Ana Lisa
  • Brand-name GLP-1s (Wegovy, Ozempic, Zepbound, Mounjaro, Foundayo) covered by major PPO and Medicare at copay
  • Compounded semaglutide from $99/month with free 2-day shipping, syringes, and supplies included via 503A/503B pharmacy
  • 1:1 registered dietitian (RDN) and monthly video provider visits included in every plan; unlimited chat and app support
  • Cellular smart scale provided to qualifying patients for ongoing weight tracking throughout the program

Where it loses points

  • Currently available only in California, Florida, New York, and Texas — 46 states unserved despite announced expansion
  • Telehealth subscription ($99/mo self-pay, $49 first-month promo) is charged separately from compounded medication cost
  • Labs not included — $75 flat rate for uninsured patients; baseline bloodwork may be required before prescribing
  • No LegitScript certification found on any public page
  • Compounding pharmacy partner not named publicly; 503A/503B status claimed but specific pharmacy undisclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard